Paid Clinical Trials Memphis
Discover 564 paid clinical trials in Memphis, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
AtogepantA Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Sponsor:
AbbVie
Location:
Code:
NCT05711394
Conditions
Episodic Migraine
Eligibility Criteria
Sex: All
Age: 6 - 17
Healthy Volunteers: Not accepted
Interventions
Atogepant
Placebo-Matching Atogepant
Observational StudyIdentification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Sponsor:
St. Jude Children's Research Hospital
Location:
Code:
NCT06289673
Conditions
Acute Lymphoblastic Leukemia
Lymphoblastic Lymphoma
Mixed Phenotype Acute Leukemia
Eligibility Criteria
Sex: All
Age: 1 - 18
Healthy Volunteers: Not accepted
Interventions
Dexamethasone
Vincristine
Daunorubicin
Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)
Methotrexate
PembrolizumabLong-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT03486873
Conditions
Solid Tumors
Hematologic Malignancies
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
Standard of Care (SOC)
Lenvatinib
Olaparib
MK-4280
PDA TreatmentPREEMIE: Study for Treatment of PDA in Premature Infants
Sponsor:
Merit Medical Systems, Inc.
Location:
Code:
NCT06587282
Conditions
Patent Ductus Arteriosus (PDA)
Eligibility Criteria
Sex: All
Age: 5+
Healthy Volunteers: Not accepted
Interventions
Bloom Micro Occluder System
Observational StudyNational Collaborative to Improve Care of Children With Complex Congenital Heart Disease
Sponsor:
Children's Hospital Medical Center, Cincinnati
Location:
Code:
NCT02852031
Conditions
Hypoplastic Left Heart Syndrome (HLHS)
Eligibility Criteria
Sex: All
Age: 0 - 15
Healthy Volunteers: Not accepted
Interventions
Collaborative Learning Network
Methylation BiomarkersNon-Endoscopic Detection of Barrett's Esophagus Using Methylation Biomarkers on EndoSign® Cell Collection Device Samples
Sponsor:
Cyted Health Inc
Location:
Code:
NCT06803927
Conditions
Barrett Esophagus
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Barrett's Esophagus Test (LDT)
Integrity Implant SystemIntegrity Implant System Post Market Clinical Follow-Up Study
Sponsor:
Anika Therapeutics, Inc.
Location:
Code:
NCT06741527
Conditions
Rotator Cuff Tears of the Shoulder
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Integrity Implant System
Surgery vs. TreatmentComparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Sponsor:
Alliance for Clinical Trials in Oncology
Location:
Code:
NCT06632327
Conditions
Resectable Lung Non-Small Cell Carcinoma
Stage II Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Surgical Procedure
Cisplatin
Carboplatin
Pemetrexed
Gemcitabine
Talquetamab, Daratumumab, PomalidomideA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
Sponsor:
Janssen Research & Development, LLC
Location:
Code:
NCT05455320
Conditions
Relapsed or Refractory Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Talquetamab
Daratumumab
Pomalidomide
Dexamethasone
Petosemtamab vs. PembrolizumabA Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Sponsor:
Merus N.V.
Location:
Code:
NCT06525220
Conditions
Head and Neck Squamous Cell Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Petosemtamab
Pembrolizumab